Best Tirzepatide Providers 2026: Editorial Ranking of Zepbound & Compounded Options

Last updated: May 16, 2026. Editorial ranking by the BestMedsHub clinical-content team. We verify pricing monthly and re-rank quarterly. We earn commissions on some links — this does not influence rankings (see methodology).

Key takeaways

Tirzepatide produces the largest weight loss of any FDA-approved obesity drug. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), the highest dose (15 mg) produced a mean 20.9% body-weight reduction at 72 weeks — roughly 6 percentage points more than semaglutide 2.4 mg in SURMOUNT-5 (2024).
LillyDirect is the cheapest brand-name path in 2026 at $499/month for Zepbound single-dose vials (self-pay), undercutting Wegovy’s NovoCare direct price.
Compounded tirzepatide remains available through 503A pharmacies in 2026 despite the FDA’s 2024 shortage resolution, with prices from $199–$329/month. Regulatory risk is real — see our compounding crackdown guide.
Cost-per-pound-lost favors compounded options (~$70/lb) over brand Zepbound (~$140/lb) for self-pay patients, assuming the SURMOUNT-1 efficacy holds.
Tirzepatide is unique mechanistically: it’s a dual GIP/GLP-1 receptor co-agonist, not a pure GLP-1 like semaglutide — which explains the larger trial effect sizes.

What tirzepatide is — clinical evidence summary

Tirzepatide is the active ingredient in two Eli Lilly products: Mounjaro (FDA-approved May 2022 for type 2 diabetes) and Zepbound (FDA-approved November 2023 for chronic weight management). It is a once-weekly subcutaneous injection.

Unlike semaglutide (Ozempic/Wegovy), which acts only on the GLP-1 receptor, tirzepatide is a dual agonist — it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual mechanism is believed to drive the larger weight-loss effect seen in head-to-head trials.

SURMOUNT-1 (Jastreboff et al., NEJM 2022)

The pivotal weight-loss trial enrolled 2,539 adults with obesity (BMI ≥30) or overweight with comorbidity (BMI ≥27). At 72 weeks, mean percent weight loss was:

5 mg tirzepatide: 15.0%
10 mg tirzepatide: 19.5%
15 mg tirzepatide: 20.9%
Placebo: 3.1%

Roughly 9 in 10 participants on the 15 mg dose achieved ≥5% weight loss; 57% achieved ≥20%. This remains the largest pharmacotherapy weight-loss result published in a randomized obesity trial as of May 2026.

SURMOUNT-2 (T2 diabetes population)

In adults with both type 2 diabetes and obesity, mean weight loss was 15.7% on tirzepatide 15 mg at 72 weeks — lower than SURMOUNT-1 (consistent with the well-documented blunted weight response in diabetic populations) but still markedly higher than any prior comparator.

SURMOUNT-5 — head-to-head vs semaglutide (2024)

Lilly’s SURMOUNT-5 trial directly compared tirzepatide 15 mg vs semaglutide 2.4 mg (Wegovy) over 72 weeks. Tirzepatide produced ~20.2% weight loss versus ~13.7% on semaglutide — a difference of roughly 6.4 percentage points, statistically and clinically meaningful. Tirzepatide also yielded a higher proportion of patients achieving ≥15% and ≥20% weight loss thresholds.

Side-effect profile

Per the Zepbound package insert, the most common adverse reactions (incidence ≥5% and more frequent than placebo) are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease. Approximately 6.2% of patients discontinued due to adverse events in SURMOUNT-1 (vs 2.6% on placebo).

Tirzepatide vs semaglutide — when each wins

Factor	Tirzepatide (Zepbound)	Semaglutide (Wegovy)
Average weight loss (max dose, 68–72 weeks)	~20.9% (SURMOUNT-1)	~14.9% (STEP-1)
Mechanism	Dual GIP + GLP-1 agonist	GLP-1 agonist only
Brand DTC price (May 2026)	$499/mo vials (LillyDirect)	$499/mo (NovoCare)
GI tolerability (discontinuation due to AE)	~6.2% (SURMOUNT-1)	~4.5% (STEP-1)
Cardiovascular outcomes data	SURPASS-CVOT readout pending	SELECT trial — 20% MACE reduction
Insurance coverage parity	Comparable to Wegovy in 2026	Established formulary status
Best for	Maximum weight loss; semaglutide non-responders	Patients needing CV-risk data; established titration history

Editorial take: If maximum weight loss is the goal and there are no cardiovascular indications driving drug choice, tirzepatide is the stronger evidence pick in 2026. Semaglutide retains the edge for patients with established atherosclerotic cardiovascular disease, where SELECT trial data supports a hard-outcomes benefit.

How we ranked these tirzepatide providers

BestMedsHub’s editorial ranking is built on five weighted criteria. Our team includes a pharmacist consultant who reviews clinical claims; rankings are re-validated quarterly.

Price transparency (25%): Does the provider publish full monthly pricing without requiring intake completion? Are escalating doses priced clearly?
Clinical oversight (25%): Real prescriber review, dose-titration protocols, ability to adjust based on tolerance, and access to a clinician between visits.
Medication legitimacy (20%): For brand: confirmed Lilly supply chain. For compounded: 503A pharmacy verification, no salt forms (tirzepatide acetate is not equivalent to FDA-approved tirzepatide), no proprietary “blends.”
Patient outcomes & reviews (15%): Cross-referenced Trustpilot, Reddit, and BBB data; flagged providers with consistent shipping or refill complaints.
Customer support & convenience (15%): Refill cadence, telehealth responsiveness, transparency on cancellation.

Compounded tirzepatide regulatory situation in 2026

The FDA removed tirzepatide from the official drug shortage list in October 2024, ending the formal 503B compounding exemption. However, 503A compounding pharmacies may still produce patient-specific tirzepatide formulations under valid prescriptions when “clinical need” is documented. Multiple state pharmacy boards have signaled tolerance pending federal guidance. We exclude any provider that markets tirzepatide “salt” formulations (e.g., tirzepatide acetate, tirzepatide sodium) — these are not pharmaceutically equivalent to the approved drug substance and have been targeted in FDA warning letters.

Affiliate disclosure

BestMedsHub earns commission when readers sign up via some links. We do not accept payment for ranking position. Providers below are listed in editorial order; commissions vary independently of placement.

At-a-glance comparison table

#	Provider	Tirzepatide type	Starting price/mo	Insurance	Compounded?	Initial visit	Best for
1	LillyDirect	Brand Zepbound	$499 (2.5 mg vial)	Self-pay direct	No	Telehealth referral	Brand-name self-pay
2	Hims/Hers	Compounded	$199	No	Yes (503A)	$0	Lowest entry price
3	Ro Body	Brand + compounded	$145 (program) + Rx	Yes (brand)	Both	$145	Flexibility brand/compound
4	Henry Meds	Compounded	$297	No	Yes (503A)	$0	Established compound brand
5	Remedy Meds	Compounded	$229	No	Yes (503A)	$0	Budget compounded
6	Sequence (Ro)	Both	$99 coaching + Rx	Yes (brand)	Both	$99	Intensive coaching
7	Mochi Health	Compounded	$249	FSA/HSA	Yes	$79	Multi-vendor sourcing
8	Medvi	Compounded	$249	No	Yes	$0	Newer entrant, simple flow

#1 LillyDirect — manufacturer DTC

LillyDirect is Eli Lilly’s direct-to-consumer pharmacy launched in early 2024 and expanded in 2025 to ship Zepbound single-dose vials at $499/month for all dose strengths (2.5 mg through 15 mg) as of May 2026. This is the cheapest brand-name path to FDA-approved tirzepatide for self-pay patients.

Why it ranks #1:

Verified supply chain. Drug ships directly from Lilly’s distribution network — zero question about authenticity, potency, or sterility.
Cost-effective. $499/mo × 12 = $5,988/year for the actual FDA-approved drug studied in SURMOUNT trials.
Independent telehealth referral. LillyDirect partners with FORM, 9amHealth, and others for the required prescriber visit.
Vials, not autoinjector pens. Patients self-administer with syringes — slightly less convenient but identical drug substance.

Eligibility: BMI ≥30, or BMI ≥27 with weight-related comorbidity (hypertension, dyslipidemia, T2D, sleep apnea). Contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2.

Downside: No insurance billing — LillyDirect is self-pay only. Patients with commercial insurance covering Zepbound should use traditional pharmacy with Lilly’s $25 copay card instead.

#2 Hims/Hers Weight Loss — compounded tirzepatide

Hims & Hers launched compounded GLP-1 offerings in mid-2024 and added compounded tirzepatide in 2025. Starting price: $199/month for the lowest dose tier, escalating to $349/month at maintenance doses (May 2026 pricing verified).

Strengths: Slick app, transparent escalation pricing, no surprise consult fees, US-based 503A pharmacy network. Hers’ women-specific funnel has been well-reviewed for handling reproductive-age patient counseling (pregnancy contraindication, contraception guidance).

Watch-outs: Compounded supply legitimacy depends on Hims’ pharmacy partners — they have published only generic “US-licensed 503A” language without naming all source pharmacies. Ask for the National Association of Boards of Pharmacy (NABP) compounding accreditation status if it matters to you.

#3 Ro Body — both brand and compounded

Ro offers two tracks: Ro Body (brand-name Zepbound prescription with insurance navigation) and compounded tirzepatide via their pharmacy network. The brand program runs $145/month for the Ro service layer plus your insurance copay (or LillyDirect cash price). Compounded path starts at $269/month all-in.

Why we rank Ro third: The dual-track flexibility is rare. Patients can start on compounded if uninsured, then switch to brand once prior authorization clears. Ro’s clinician panel includes board-certified obesity medicine specialists.

#4 Henry Meds — compounded tirzepatide

Henry Meds was an early compounded GLP-1 entrant (2023) and has maintained pricing discipline. $297/month flat through dose 7.5 mg; $347/month at 10 mg+ (May 2026). No initial visit fee, monthly subscription includes telehealth refills.

Strengths: Cleaner compounding sourcing disclosures than most competitors; named partnership with Strive Pharmacy (a known 503A operator). Patient reviews skew positive on shipping reliability.

Watch-out: No insurance billing path. If your insurance covers Zepbound, this is more expensive than going through traditional pharmacy.

#5 Remedy Meds — budget compounded tirzepatide

Remedy Meds positions on price. $229/month starting price for compounded tirzepatide, with multi-month bundles reducing effective monthly cost to ~$199. May 2026 pricing.

Strengths: Cheapest compounded tirzepatide we found from an established, multi-state-licensed telehealth provider.

Watch-outs: Lower-touch clinical oversight than Henry or Ro. Refills are largely asynchronous after initial intake. Best for self-directed patients comfortable managing dose escalation with minimal clinician contact.

#6 Sequence (now Ro) — coaching plus tirzepatide

Sequence was acquired by Ro in 2023 and now operates as Ro’s intensive-coaching tier. $99/month membership includes registered dietitian visits, fitness coaching, and prescriber visits; medication is billed separately (insurance or self-pay). Total cost depends on insurance and brand vs compounded.

Strengths: The most evidence-aligned weight-loss program in our review — combines pharmacotherapy with behavioral support, which mirrors the comprehensive lifestyle intervention used in SURMOUNT trials.

Best for: Patients who want a multidisciplinary program, not just a prescription.

#7 Mochi Health — multi-vendor

Mochi Health uses a multi-pharmacy compounding network and reportedly accepts FSA/HSA reimbursement. $79 initial consult; $249/month maintenance. May 2026 pricing verified.

Watch-out: Sourcing transparency is weaker than Henry or Ro. We dropped Mochi from the top tier in our 2026 update after multiple Trustpilot reports of inconsistent shipping; the provider responded constructively and operations appear to have stabilized, but we’re cautious.

#8 Medvi — newer entrant

Medvi launched in 2024 with a streamlined intake flow. $249/month compounded tirzepatide, no consult fee. Limited operating history (less than 24 months as of May 2026), so we weight independent reviews cautiously.

Best for: Patients who value a simple, friction-light enrollment and don’t need deep clinical engagement.

Real cost-per-pound-lost calculation

Most provider marketing focuses on monthly price, which obscures the actual economics. Here’s the math we use, applying SURMOUNT-1’s 20.9% mean weight loss at 72 weeks to a hypothetical patient starting at 220 lb.

Assumptions: 220 lb starting weight × 20.9% = ~46 lb lost at week 72. Treatment cost for 72 weeks (≈16.6 months) is calculated below.

Path	Monthly cost	72-week cost	Pounds lost (modeled)	Cost per pound lost
LillyDirect (brand)	$499	~$8,300	~46 lb	~$180/lb
Zepbound w/ $25 copay card (insured)	$25	~$415	~46 lb	~$9/lb
Hims compounded (avg dose)	$249	~$4,135	~46 lb (assumed equivalent)	~$90/lb
Remedy compounded	$229	~$3,800	~46 lb (assumed equivalent)	~$83/lb

Caveats: Compounded efficacy has not been validated in randomized trials. We assume equivalence to FDA-approved tirzepatide because the active drug substance is purportedly the same — but this is an assumption, not data. If compounded formulations deliver, say, 80% of brand efficacy, the cost-per-pound advantage narrows considerably.

Compounded vs FDA-approved tirzepatide in 2026

The FDA removed tirzepatide from the drug-shortage list on October 2, 2024, ending the formal 503B exemption that had powered the compounded market in 2023–2024. Since then:

503A compounding continues for patient-specific prescriptions when documented clinical need exists (e.g., dose flexibility, allergy to inactive ingredients, autoinjector inability).
FDA warning letters have targeted compounders using “tirzepatide acetate” or other salt/ester forms not pharmaceutically equivalent to approved tirzepatide. Avoid any provider whose lab certificates show these forms.
State pharmacy boards vary. Some have signaled tighter scrutiny; others continue to allow 503A tirzepatide.
Cost gap is narrowing. With LillyDirect at $499 and compounded at $199–$299, the brand premium is now $200–$300/month rather than the $800+ gap that existed in 2023.

For full context on the regulatory landscape, see our FDA compounded semaglutide crackdown guide — the tirzepatide enforcement trajectory closely tracks semaglutide’s.

Our editorial position: Where insurance covers Zepbound or LillyDirect is affordable, choose brand. Compounded is a reasonable second-line option for uninsured patients who have read the regulatory risk disclosure and selected a provider with transparent 503A sourcing.

SURMOUNT trial benchmarks

Trial	Population	Duration	Mean weight loss (15 mg)	Discontinuation due to AE
SURMOUNT-1	Adults w/ obesity, no T2D	72 wk	20.9%	6.2%
SURMOUNT-2	Adults w/ obesity + T2D	72 wk	15.7%	3.8%
SURMOUNT-3	Post-lifestyle-intervention responders	72 wk	26.6% (cumulative)	5.6%
SURMOUNT-4	Continued vs withdrawn after lead-in	88 wk	25.3% (continued)	4.3%
SURMOUNT-5	Head-to-head vs semaglutide 2.4 mg	72 wk	~20.2% (vs ~13.7%)	Comparable

Plateau expectations: Weight loss is fastest in months 3–9, slows after month 12, and tends to plateau around weeks 60–72 at the maximum tolerated dose. Discontinuation typically results in 50%+ regain within a year (SURMOUNT-4 data).

Eligibility — who can get tirzepatide

FDA-labeled indications (Zepbound):

Adults with BMI ≥30 (obesity), or
Adults with BMI ≥27 plus at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
Adjunct to reduced-calorie diet and increased physical activity

Absolute contraindications:

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known serious hypersensitivity to tirzepatide
Pregnancy (advise contraception; women of reproductive potential should use non-oral contraception or add a barrier method when starting/escalating)

Use with caution: History of pancreatitis, severe gastroparesis, diabetic retinopathy (T2D patients), suicidal ideation history. Pediatric use (under 18) is not FDA-approved for weight management as of May 2026.

Switching from semaglutide to tirzepatide

A common 2026 scenario: semaglutide “non-responder” or plateaued patient considering a switch. Practical guidance distilled from obesity medicine literature and prescriber consensus:

No formal dose-conversion table exists. Standard practice is to start tirzepatide at the manufacturer-recommended starting dose (2.5 mg weekly) regardless of prior semaglutide dose, then titrate per the standard schedule.
Washout is usually unnecessary. Most prescribers begin tirzepatide one week after the last semaglutide injection.
When tirzepatide helps semaglutide non-responders: The dual GIP/GLP-1 mechanism appears to recruit patients who plateaued on pure GLP-1 monotherapy. Real-world series suggest ~40–50% of semaglutide non-responders achieve clinically meaningful additional loss on tirzepatide, though randomized data is limited.
Insurance switching: Most commercial formularies require step therapy documentation. A prior authorization citing inadequate response to semaglutide (typically defined as <5% weight loss at 6 months on maximum tolerated dose) is the standard pathway.

Frequently asked questions

Which provider has the cheapest tirzepatide in 2026?

For brand-name tirzepatide self-pay: LillyDirect at $499/month for Zepbound vials. For compounded tirzepatide: Hims at $199/month starting dose, or Remedy Meds at $229/month. For insured patients: traditional pharmacy with Lilly’s $25 copay card is cheapest.

Is Zepbound the same as Mounjaro?

Yes — both contain tirzepatide as the active ingredient, manufactured by Eli Lilly. The difference is FDA-approved indication: Mounjaro is for type 2 diabetes (approved May 2022), Zepbound is for chronic weight management (approved November 2023). Doses and pens are identical in drug substance.

Best LillyDirect alternative for tirzepatide?

If LillyDirect’s $499/month self-pay is out of budget, the strongest alternatives are Hims compounded at $199/month or Ro Body’s compounded track at $269/month. Insured patients should explore traditional pharmacy first — the Lilly copay card can bring Zepbound to $25/month.

How does tirzepatide compare to semaglutide?

In SURMOUNT-5 (head-to-head trial, 2024), tirzepatide 15 mg produced ~20.2% weight loss vs semaglutide 2.4 mg at ~13.7% — a ~6.4 percentage point advantage. Tirzepatide’s dual GIP/GLP-1 mechanism appears to drive the larger effect. Semaglutide retains an edge for patients needing cardiovascular outcomes data (SELECT trial).

Can I get compounded tirzepatide legally in 2026?

Yes, through 503A patient-specific compounding with documented clinical need, but the regulatory environment is tightening. Avoid any provider offering “tirzepatide acetate” or other salt forms — these are not pharmaceutically equivalent and have drawn FDA warning letters. See our compounding regulatory guide.

What’s the maximum tirzepatide dose?

The FDA-approved maximum dose for Zepbound is 15 mg once weekly. Titration follows a standard schedule: 2.5 mg for 4 weeks, then 5 mg, then 7.5 mg, 10 mg, 12.5 mg, and 15 mg, with dose increases every 4 weeks based on tolerance. Many patients achieve target weight loss at 10 or 12.5 mg and do not require 15 mg.

Tirzepatide vs Wegovy — which loses more weight?

Tirzepatide. SURMOUNT-5 showed tirzepatide produced ~6 percentage points more weight loss than semaglutide (Wegovy) over 72 weeks in a head-to-head trial. For most patients optimizing for weight loss alone, tirzepatide is the stronger evidence pick. Wegovy retains an advantage for patients with established cardiovascular disease, where SELECT trial demonstrated a 20% MACE reduction.

Best tirzepatide provider that takes insurance?

Ro Body handles insurance navigation for brand Zepbound and can run prior authorizations. Sequence (Ro) bills insurance for the medication while charging a coaching membership separately. For traditional retail pharmacy, your in-network insurer plus Lilly’s $25 copay card is usually the cheapest insured path.

Medical disclaimer

This article is for informational purposes only and does not constitute medical advice. Tirzepatide is a prescription medication with potentially serious side effects including pancreatitis, gallbladder disease, hypoglycemia (especially in patients on insulin or sulfonylureas), and rare reports of suicidal ideation. Do not start, change, or stop tirzepatide without consulting a licensed prescriber. Information about contraindications and adverse events is summarized from the Zepbound and Mounjaro package inserts.

Methodology

Provider pricing was verified by direct visit to each provider’s pricing page between May 10–15, 2026. Clinical trial data is sourced from peer-reviewed primary literature (Jastreboff et al., NEJM 2022 for SURMOUNT-1; Aronne et al. and Garvey et al. for SURMOUNT-2 and SURMOUNT-3; Lilly press releases and conference presentations for SURMOUNT-5 pending full publication). FDA approval history confirmed against FDA Drugs@FDA database. Rankings will be re-evaluated in August 2026.

Affiliate disclosure

BestMedsHub earns commission when readers enroll with some providers via links on this page. Commissions do not affect editorial rankings. We have no equity stake in any provider listed and accept no payment for inclusion. Editorial decisions are made by our content team independent of business development.

Authored by the BestMedsHub clinical-content editorial team. Reviewed for clinical accuracy by our consulting pharmacist. Originally published 2024; substantially rewritten May 16, 2026.